KACY CLINKENBEARD: Open Payments
NPI 1417579269 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,438 in 133 payments from 20 companies in 2025. Trend: 2023 $1,223 · 2024 $1,924 · 2025 $2,438
Food & beverage: $2,323Education: $114
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $630 |
| Janssen Biotech, Inc. | 16 | $469 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 27 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $182 |
| GENZYME CORPORATION | 9 | $175 |
| Gilead Sciences, Inc. | 6 | $139 |
| Phathom Pharmaceuticals, Inc. | 10 | $130 |
| Ardelyx, Inc. | 4 | $87 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Sandoz Inc. | 2 | $47 |
Products named: TREMFYA, RINVOQ, XIFAXAN, DUPIXENT, ENTYVIO, LINZESS, VOQUEZNA, CREON.
Industry payments across SC — which companies pay providers there.
